ARCHIVES

Ivax Paclitaxel To Remain On Market In Deal With BMS.

This article is from The Cancer Letter archive.

Vol. 28 No. 05 | February 1, 2002

Download PDF Visit The Full Archive

Related Articles

Bunn Says ASCO Is “Strong, Diverse, Respected, Growing”

June 6, 2003

Ilex Oncology Buys Symphar, Controls Drug For Bone Mets.

March 2, 2001

Foreign awards Less Than 1% Of NCI Budget

June 22, 1990

NCI plans 18 percent budget cuts for large R01s, smaller cuts to other research project grants. NCI treatment division director Ellen Feigal accepts position with Translational Genomics Research Institute in Phoeniz, Ariz.

March 12, 2004

Sense Of Excitement, Challenges, Mark Healy’s Debut

April 26, 1991

PhRMA’s New Ethics Code Prohibits Trinkets, Dinners; Speaking Fees Still OK.

July 11, 2008